Information Provided By:
Fly News Breaks for February 7, 2019
SLDB, SRPT
Feb 7, 2019 | 08:37 EDT
The microdystrophin expression data reported this morning by Solid Biosciences (SLDB) "pales in comparison" to those from Sarepta Therapeutics, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. Shares of Sarepta are up 6.5% to $150.76 in premarket trading while Solid Biosciences is down 71%, or $15.84, to $6.50. Unfortunately, Solid's construct has elicited complement activation that necessitated the use of eculizumab, which might restrict the therapeutic window as the program advances, Chattopadhyay writes. He believes that if the trajectory of Solid's data holds, Sarepta's 12 to 18-month lead is "insurmountable." The analyst has a Buy rating on Sarepta with a $267 price target.